Breen Michael Martin
- SEC CIK
- 0001863633
No open-market purchases or sales filed in the past year.
Current role at each company
- GTBP GT Biopharma, Inc.CEO and Directoras of Sep 8, 2025
- PROP Prairie Operating Co.Directoras of May 5, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Breen Michael Martin as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
PROP Prairie Operating Co.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 5, 2023 (view filing)9:43 PM ET | May 3 | 2 days | Breen Michael MartinDirector | PPurchase | +916.1K | $0.109 | +$99.9K | +9,161.1%926.1K after |
GTBP GT Biopharma, Inc.
CEO and Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 11, 2023 (view filing) | Apr 11 | Same day | Breen Michael MartinExecutive Chairman/Interim CEO | PPurchase | +50.0K | $0.50 | +$25.0K | +8.2%656.2K after |